{"nctId":"NCT02227706","briefTitle":"The Paediatric EVICEL® Soft Tissue and Parenchymal Organ Bleeding Study","startDateStruct":{"date":"2014-08-01","type":"ACTUAL"},"conditions":["Hemorrhage","Soft Tissue Bleeding"],"count":40,"armGroups":[{"label":"EVICEL® Fibrin Sealant","type":"EXPERIMENTAL","interventionNames":["Biological: EVICEL® Fibrin Sealant"]},{"label":"SURGICEL® Absorbable Hemostat","type":"ACTIVE_COMPARATOR","interventionNames":["Device: SURGICEL® Absorbable Hemostat"]}],"interventions":[{"name":"EVICEL® Fibrin Sealant","otherNames":["EVICEL, fibrin sealant"]},{"name":"SURGICEL® Absorbable Hemostat","otherNames":["oxidized regenerated cellulose"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Paediatric subjects birth to \\<18 years of age, requiring non-emergent laparoscopic or open (through peritoneum or pleura) abdominal, retroperitoneal, pelvic or thoracic (non-cardiac) surgical procedures. i) The first 36 subjects to be enrolled will be subjects ≥1 years to \\<18 years of age. ii) The next 4 subjects to be enrolled will be subjects birth to \\<1years of age.\n* The subject and/or subject's parent or legal guardian must be willing to give permission for the subject to participate in the trial, and provide written informed consent for the subject. If possible, assent must be obtained from paediatric subjects who possess the intellectual and emotional ability to comprehend the concepts involved in the trial. If the paediatric subject is not able to provide assent (due to age, maturity and/or inability to intellectually and/or emotionally comprehend the trial), the parent/legal guardian's written informed consent for the subject will be acceptable for the subject to be included in the study; and\n* Presence of an appropriate mild or moderate bleeding soft tissue or parenchymal organ Target Bleeding Site identified intra-operatively by the surgeon;\n\nExclusion Criteria:\n\n* Subjects with known intolerance to blood products or to one of the components of the study product or is unwilling to receive blood products;\n* Female subjects, who are of childbearing age (i.e. adolescent), who are pregnant or nursing;\n* Subject is currently participating or, during the study is planned to participate in any other investigational device or drug trial without prior approval from the Sponsor;\n* Subjects who are known, current alcohol and/or drug abusers;\n* Subjects admitted for trauma surgery;\n* Subjects with any pre or intra-operative findings identified by the surgeon that may preclude conduct of the study procedure;\n* Subjects with Target Bleeding Site in an actively infected field (Class III Contaminated or Class IV Dirty or Infected)\n* Anastomotic bleeding sites will not be considered for randomization.","healthyVolunteers":false,"sex":"ALL","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Time to Haemostasis","description":"Absolute time to haemostasis, defined as absolute time when there was no detectable bleeding at the Target Bleeding Site (TBS).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":null},{"groupId":"OG001","value":"4.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving Haemostasis at 4 Minutes","description":"Number of participants achieving haemostasis at target bleeding site at 4 minutes. This endpoint is assessing haemostasis at 4 minutes only and not maintenance of haemostasis following this timepoint. As rebleeding may occur between timepoints, subsequent rebleeding (if any) is detailed in treatment failure analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving Haemostasis at 7 Minutes","description":"Number of Participants Achieving Haemostasis at Target Bleeding Site at 7 Minutes. This endpoint is assessing haemostasis at 7 minutes only and is not affected by haemostasis assessment prior to 7 minutes or maintenance of haemostasis following this 7 minute assessment. As rebleeding may occur between timepoints, subsequent rebleeding (if any) is detailed in treatment failure analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving Haemostasis at 10 Minutes","description":"Number of Participants Achieving Haemostasis at Target Bleeding Site at 10 Minutes. This endpoint is assessing haemostasis at 10 minutes only and is not affected by haemostasis assessments prior to 10 minutes or maintenance of haemostasis following this 10 minute assessment. As rebleeding may occur between timepoints, subsequent rebleeding (if any) is detailed in treatment failure analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Treatment Failures (Number of Participants)","description":"Defined as haemostasis not achieved within 10 minutes or bleeding requiring treatment other than re-application of the assigned haemostatic adjunct within 10 minutes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Estimated Blood Loss","description":"Blood loss during surgical procedure (includes but not limited to the target bleeding site)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Blood Transfusion","description":"Participants requiring a blood transfusion","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Receiving a Blood Transfusion","description":"Details of blood products received (if any)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in Laboratory Parameters Haemoglobin and Mean Corpuscular Haemoglobin Concentration","description":"Laboratory parameter changes from baseline to post operative hospital discharge (Haemoglobin and Mean Corpuscular Haemoglobin Concentration)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.2","spread":"21.5"},{"groupId":"OG001","value":"-10.6","spread":"8.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.3","spread":"6.7"},{"groupId":"OG001","value":"-3.4","spread":"11.9"}]}]}]},{"type":"SECONDARY","title":"Changes in Laboratory Parameters Haematocrit","description":"Change in red blood cell proportion in volume in the blood from baseline to post operative hospital discharge","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.0"},{"groupId":"OG001","value":"-0.0","spread":"0.0"}]}]}]},{"type":"SECONDARY","title":"Changes in Laboratory Parameters Platelet Count and White Cell Count","description":"Laboratory parameter changes from baseline to post operative hospital discharge","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.4","spread":"159.3"},{"groupId":"OG001","value":"7.6","spread":"96.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"5.2"},{"groupId":"OG001","value":"1.4","spread":"4.3"}]}]}]},{"type":"SECONDARY","title":"Changes in Laboratory Parameters Red Blood Cell Count","description":"Laboratory parameter changes from baseline to post operative hospital discharge","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.5"},{"groupId":"OG001","value":"-0.4","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Changes in Laboratory Parameters Mean Corpuscular Haemoglobin","description":"Laboratory parameter changes from baseline to post operative hospital discharge","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.1"},{"groupId":"OG001","value":"0.2","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Changes in Laboratory Parameters Mean Corpuscular Volume","description":"Laboratory parameter changes from baseline to post operative hospital discharge","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"2.6"},{"groupId":"OG001","value":"1.5","spread":"3.2"}]}]}]},{"type":"SECONDARY","title":"Changes in Laboratory Parameters Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils","description":"Laboratory parameter changes in volume from baseline to post operative hospital discharge (Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":"17.1"},{"groupId":"OG001","value":"10.1","spread":"19.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.2","spread":"13.1"},{"groupId":"OG001","value":"-11.6","spread":"17.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"6.4"},{"groupId":"OG001","value":"1.5","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.4"},{"groupId":"OG001","value":"-0.3","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Changes in Laboratory Parameters Activated Partial Thromboplastin Time and Prothrombin Time","description":"Laboratory parameter changes from baseline to post operative hospital discharge (Activated Partial Thromboplastin Time and Prothrombin Time)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"4.2"},{"groupId":"OG001","value":"-2.2","spread":"4.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"3.0"},{"groupId":"OG001","value":"0.1","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"Changes in Laboratory Parameters International Normalised Ratio","description":"Standardized measurement of the change in blood clotting time from baseline to post operative hospital discharge","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.2"},{"groupId":"OG001","value":"-0.0","spread":"0.1"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With a Thrombotic Event","description":"Number of Participants with a Thrombotic Event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With an Adverse Event Related to Re-bleeding at Target Bleeding Site","description":"Number of Participants with an Adverse Event Related to Re-bleeding at Target Bleeding Site.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":20},"commonTop":["Pyrexia","Procedural pain","Tachycardia","Vomiting","Abdominal pain"]}}}